Revelation Biosciences, Inc. (REVB)
Market Cap | 2.92M |
Revenue (ttm) | n/a |
Net Income (ttm) | -8.96M |
Shares Out | 1.63M |
EPS (ttm) | -35.39 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 33,149 |
Open | 1.940 |
Previous Close | 1.870 |
Day's Range | 1.690 - 1.940 |
52-Week Range | 1.610 - 28.800 |
Beta | 0.19 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 9, 2024 |
About REVB
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based ... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/y/u/press19-2492786.jpg)
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...
![](https://cdn.snapi.dev/images/v1/r/u/press7-2477861.jpg)
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...
![](https://cdn.snapi.dev/images/v1/d/r/press4-2425069.jpg)
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...
![](https://cdn.snapi.dev/images/v1/y/o/press17-2338187.jpg)
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...
![](https://cdn.snapi.dev/images/v1/w/n/press11-2322300.jpg)
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of ...
![](https://cdn.snapi.dev/images/v1/k/s/press17-2320108.jpg)
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of t...
![](https://cdn.snapi.dev/images/v1/a/d/press6-2306434.jpg)
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of ...
![](https://cdn.snapi.dev/images/v1/b/b/press8-2273524.jpg)
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, as part of a limited number of accepted abstract authors, t...
![](https://cdn.snapi.dev/images/v1/6/q/image-7-2269246.jpg)
Top 5 Health Care Stocks That Are Preparing To Pump In February
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/j/t/press10-2260921.jpg)
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immuni...
![](https://cdn.snapi.dev/images/v1/t/6/press3-2254838.jpg)
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immuni...
![](https://cdn.snapi.dev/images/v1/v/g/conf1-2250835.jpg)
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of...
![](https://cdn.snapi.dev/images/v1/x/s/press6-2240313.jpg)
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 25, 2024, the Company will implement a 1-for-30 ...
![](https://cdn.snapi.dev/images/v1/v/k/press13-2155534.jpg)
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immun...
![](https://cdn.snapi.dev/images/v1/r/l/press5-2100814.jpg)
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that data from recent preclinical studies of the Company's Gemini...
![](https://cdn.snapi.dev/images/v1/t/1/conf16-2089523.jpg)
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immuni...
![](https://cdn.snapi.dev/images/v1/q/u/press14-2085881.jpg)
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
![](https://cdn.snapi.dev/images/v1/n/v/press7-2020197.jpg)
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
![](https://cdn.snapi.dev/images/v1/o/t/press11-1953332.jpg)
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
![](https://cdn.snapi.dev/images/v1/c/6/press10-1930938.jpg)
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
![](https://cdn.snapi.dev/images/v1/h/d/press6-1901307.jpg)
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
![](https://cdn.snapi.dev/images/v1/a/o/press5-1820099.jpg)
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based t...
![](https://cdn.snapi.dev/images/v1/o/q/press10-1793739.jpg)
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based t...
![](https://cdn.snapi.dev/images/v1/f/y/press16-1783573.jpg)
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based t...
![](https://cdn.snapi.dev/images/v1/h/a/press13-1751782.jpg)
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc.